Profacgen Enhanced Its Trimeric Protein Production Service |...

Profacgen Enhanced Its Trimeric Protein Production Service

Сообщение 2023-09-26 02:33:21

2Кб

Profacgen, a biotechnology company that offers a diverse portfolio of protein expression services, recently enhanced its Trimeric Protein Production Service, which could have implications for the development of effective vaccines.

Protein trimerization refers to the formation of a protein trimer, which is a macromolecular structure made up of three noncovalently linked identical or non-identical subunits.

Major Tumor Necrosis Factor (TNF) biologic blockers are currently dimeric in structure, whereas some members of the TNF family are homotrimeric. A homodimeric structure with two-fold symmetry cannot perfectly dock to a homotrimeric structure with three-fold symmetry, limiting the affinity between the two molecules, according to structural biology.

Embracing the goal to bring customers a versatile and reliable platform for protein production and development, Profacgen now provides novel trimeric protein production service through design and expression of proteins in disulfide bond-linked homo-trimeric forms.

Profacgen has achieved significant improvements in the expression level of recombinant trimeric fusion proteins and optimization of purification protocols over many years of experience, and the scale can quickly move from the preclinical stage to the bedside of millions of patients. The protein trimerization technology at Profacgen creates a broadly applicable system for the production and characterization of trimeric proteins, as well as new insights into trimer assembly and maturation, which will influence the design of effective vaccines.

The protein trimerization platform at Profacgen, according to Ellen, the chief marketing staff at Profacgen, converts secreted proteins into covalently linked homotrimers with significantly increased affinity for their pathogenic targets, such as the TNF cytokine family (TNFRII, TRAIL, and so on), HIV gp120/gp41, Influenza HA, DR4, DR5, sCD4, and ApoAI. All of these structures have been created and are being developed as biopharmaceuticals to treat autoimmune diseases, cancer, AIDS, osteoporosis, and heart disease.

Other than trimeric protein production service, Profacgen offers a wide range of protein expression services including: Bacterial Expression, Animal-Free Expression, Corynebacterium glutamicum Expression Systems, Membrane Protein Expression and Purification, Baculovirus-Mammalian cell Protein Expression System, Antibiotic-free Expression System, and so on. To know more, please visit https://www.profacgen.com/protein-expression.htm.